COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN

被引：0
|
作者：
Arriola, E. [1 ]
Batteson, R. [2 ]
Hook, E. [2 ]
Wheat, H. [2 ]
Vioix, H. [3 ]
Morros, M. [4 ]
Aguila, M. [4 ]
de los Santos Real, H. [5 ]
Soberon S, Fernandez [5 ]
Brines, M. [5 ]
Vazquez, S. [6 ]
机构：
[1] Hosp Mar, Barcelona, Spain
[2] Delta Hat Ltd, Nottingham, England
[3] Merck KGaA, Healthcare Business, Darmstadt, HE, Germany
[4] Adelphi Targis, Barcelona, Spain
[5] Merck SLU, Madrid, Spain
[6] Hosp Univ Lucus Augusti, Lugo, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE146
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Sachdev, Rameet
    Stargardter, Matthew
    Tosh, Jon
    Pfeiffer, Boris M.
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (04) : 487 - 497
  • [22] Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Hook, Emma S.
    Hatswell, Anthony J.
    Batteson, Rachael L.
    Gaumond, Bruce R.
    O'Brate, Aurora
    Popat, Sanjay
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (08) : 1155 - 1163
  • [23] Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib
    Garassino, M.
    Le, X.
    Kowalski, D.
    Migliorino, M.
    Senellert, H.
    Pradera, J.
    Walling, R.
    Kato, T.
    Thomas, M.
    Smit, E.
    Gottfried, M.
    Britschgi, C.
    Johne, A.
    Scheele, J.
    Bruns, R.
    Vioix, H.
    Pfeiffer, B.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S35 - S35
  • [24] A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping
    Hook, E.
    Vioix, H.
    Batteson, R.
    McLean, T.
    Hatswell, A.
    VALUE IN HEALTH, 2022, 25 (12) : S420 - S420
  • [25] Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).
    Kim, So Yeon
    Bohlman, Stephen
    Yin, Jun
    Cheng, Haiying
    Walker, Phillip
    Dacic, Sanja
    Kim, Chul
    Khan, Hina
    Liu, Stephen V.
    Ma, Patrick C.
    Nagasaka, Misako
    Reckamp, Karen L.
    Abraham, Jim
    Uprety, Dipesh
    Halmos, Balazs
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)
    Kelly, R. J.
    Le, X.
    Luttropp, K.
    Yang, M.
    Liu, F.
    Huse, S.
    Ganz, M. L.
    Pfeiffer, B.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1088 - S1089
  • [27] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Viteri, S.
    Felip, E.
    Griesinger, F.
    Garassino, M. C.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F.
    Raskin, J.
    Thomas, M.
    Ahn, M-J.
    Vlassak, S.
    Bruns, R.
    Johne, A.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Garassino, M. C.
    Le, X.
    Kowalski, D. M.
    Migliorino, M. R.
    Senellart, H.
    Pradera, J. Fuentes
    Walling, R.
    Kato, T.
    Thomas, M.
    Smit, E. F.
    Gottfried, M.
    Britschgi, C.
    Johne, A.
    Scheele, J.
    Bruns, R.
    Vioix, H.
    Pfeiffer, B.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2020, 31 : S864 - S864
  • [30] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
12345